Please assess the completion status of the following clinical trial:

Trial Title: A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinical~* Patients (men or women) at least 18 years of age and~* Presenting with ischemic chest discomfort \>20 minutes and \<6 hours of duration suggestive of acute myocardial infarction~AND:~ECG~* ST elevation \>1mm (\>0.1mV) in two contiguous limb leads OR \>2mm (\>0.2mV) in two contiguous precordial leads~Exclusion Criteria:~CLINICAL~* Maximal systolic blood pressure \<80 mmHg AFTER initial fluid and/or pressor resuscitation~* Uncontrolled hypertension (SBP\>180 OR DBP \>110) at time of enrollment~* Ventricular fibrillation or ventricular tachycardia requiring DC cardioversion~* Sinus bradycardia (HR \<50/min), third degree or advanced second degree heart block.~* Known pregnancy~* New or suspected new left bundle branch block~BIOCHEMICAL~* Known thrombocytopenia (platelet count \<100,000)~* Known severe renal insufficiency (creatinine \>4.0 mg/dL)~INCREASED BLEEDING RISK~* Active or recent (\<1 year) bleeding or gastrointestinal hemorrhage~* Major surgery \<1 month~* Known coagulopathy, platelet disorder or history of thrombocytopenia: If a patient is known to be on chronic warfarin therapy, the International Normalized Ratio (INR) must be known to be \<1.6 in order for the patient to be included~* Known neoplasm~* Any history of hemorrhagic cerebrovascular disorder or active intracranial pathology~MEDICATIONS~* Administration of a fibrinolytic agent within 7 days~* Known allergy or contraindication to eptifibatide OR aspirin OR heparin~* Treatment with another GP IIb/IIIa inhibitor within 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intracoronary injection of eptifibatide
- 2 (Type: PLACEBO_COMPARATOR): Intra-coronary injection of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).